

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
May 11, 2022

**CLEARPOINT NEURO, INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**  
(State or other jurisdiction  
of incorporation)

**001-34822**  
(Commission  
File Number)

**58-2394628**  
(I.R.S. Employer  
Identification Number)

**120 S. Sierra Ave., Suite 100**  
**Solana Beach, California 92075**  
(Address of principal executive offices, zip code)

**(888) 287-9109**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value per share	CLPT	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02. Results of Operations and Financial Condition.**

On May 11, 2022, ClearPoint Neuro, Inc. (the "Company") issued a press release announcing its financial performance for the first fiscal quarter ended March 31, 2022. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 7.01. Regulation FD Disclosure.**

On May 11, 2022, the Company posted an updated investor presentation to its website at <http://ir.stockpr.com/clearpointneuro/investor-presentations>. A copy of the investor presentation is being furnished herewith as Exhibit 99.2. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibit is furnished herewith:

- Exhibit 99.1 [Press Release dated May 11, 2022](#)
- Exhibit 99.2 [Investor Presentation dated May 2022](#)
- Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
- 

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 11, 2022

**CLEARPOINT NEURO, INC.**

By: /s/ Danilo D'Alessandro  
Danilo D'Alessandro  
Chief Financial Officer



## ClearPoint Neuro Reports First Quarter 2022 Results

SOLANA BEACH, CA, May 11, 2022 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2022.

### **First Quarter Highlights**

- Reported record quarterly revenue of \$5.0 million, a 25% year-over-year increase;
- Installed four additional global sites with expected first cases in Q2;
- Increased biologics and drug delivery revenue to \$2.2 million, a 30% year-over-year increase;
- Achieved additional biologics and drug delivery relationships, bringing current count of active partners to approximately 45 therapeutic partners;
- Signed an agreement with Philips to enable access to technology to allow for use of the Maestro™ Brain Model in the operating room with Computed Tomography; and
- Began development of a proprietary patient-facing digital health app for drug delivery and brain-computer interface with Higgs-Boson Health to concentrate patient resources, reduce postponements and track quality of life data before and after treatments.

### **Business Outlook**

- The Company is increasing the low-end revenue range estimate and now expects full year 2022 revenue between \$21.0 and \$22.0 million.

“The ClearPoint Neuro Team has continued to execute against our four-pillar growth strategy in the first quarter and celebrated a number of successes along the way to get 2022 off to a great start,” commented Joe Burnett, President and CEO. “First, we achieved record quarterly revenue in both Functional Neurosurgery Navigation and Biologics and Drug Delivery, yielded total revenue of \$5.0 million which represents first quarter year-over-year growth of 25%. These results were achieved in spite of Omicron related surgery cancellations and postponements, particularly throughout January and early February in the United States and Europe. Our Biologics and Drug Delivery team added additional partners, bringing our current total to approximately 45. The Functional Neurosurgery Navigation team successfully tested pre-clinical prototypes for Micro-Electric Recording and Brain Computer Interface navigation systems in collaboration with BlackRock Neurotech, and submitted ClearPoint Array 1.1 software to the FDA which has subsequently been approved here in the second quarter. Our Therapy Team continues to work with the FDA and Clinical Trial sites in the EU to advance the ClearPoint Neuro-exclusive laser platform and we continue to expect first human cases in the second half of 2022. Our strong first quarter gives our team confidence to increase our range of expected revenue for 2022 to between \$21.0 and \$22.0 million which would represent between 30 – 35% growth year-over-year.”

### **Financial Results – Quarter Ended March 31, 2022**

Total revenue was \$5.0 million for the three months ended March 31, 2022, and \$4.0 million for the three months ended March 31, 2021, which represents an increase of \$1.0 million, or 25%.

Functional neurosurgery navigation and therapy revenue, increased 17% to \$2.2 million for the three months ended March 31, 2022, from \$1.9 million for the same period in 2021. The growth was driven by higher service revenue.

Biologics and drug delivery revenue, which includes sales of disposable products and services related to customer-sponsored clinical trials utilizing our products, increased 30% to \$2.2 million for the three months ended March 31, 2022, from \$1.7 million for the same period in 2021. This increase was fueled by growth in service revenue.

Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software, and of related services, increased 41% to \$0.6 million for the three months ended March 31, 2022, from \$0.5 million for the same period in 2021.

Gross margin for the three months ended March 31, 2022, was 65%, in line with the same period in 2021.

Operating expenses for the first quarter of 2022 were \$7.1 million, compared to \$4.8 million for the first quarter of 2021. The increase was mainly driven by the increase in headcount and product development expenses.

At March 31, 2022, the Company had cash and cash equivalents totaling \$49.7 million as compared to \$54.1 million at December 31, 2021, with the decrease resulting primarily from the use of cash in operating activities.

### **Teleconference Information**

Investors and analysts are invited to listen to a live broadcast review of the Company's 2022 first quarter on Tuesday, May 11, 2022 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online [here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Yok3Gw2w](https://event.choruscall.com/mediaframe/webcast.html?webcastid=Yok3Gw2w). Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until June 10, 2022, by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the

broadcast will be available on the Company's website at [www.clearpointneuro.com](http://www.clearpointneuro.com), on the "Investor Relations" page.

### **About ClearPoint Neuro**

ClearPoint Neuro's mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company's current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with approximately 45 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 5,000 cases have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit [www.clearpointneuro.com](http://www.clearpointneuro.com).

### **Forward-Looking Statements**

Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic and the measures adopted to contain its spread; future revenue from sales of the Company's ClearPoint Neuro Navigation System products; the Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation System products; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which has been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2022, which the Company intends to file with the Securities and Exchange Commission on or before May 16, 2022.

### **Contact:**

Danilo D'Alessandro, Chief Financial Officer  
(949) 900-6833  
[info@clearpointneuro.com](mailto:info@clearpointneuro.com)

Caroline Corner, Investor Relations  
[ir@clearpointneuro.com](mailto:ir@clearpointneuro.com)

**CLEARPOINT NEURO, INC.**  
**Consolidated Statements of Operations**  
**(Unaudited)**  
**(Dollars in thousands, except for per share data)**

	For The Three Months Ended March 31,	
	2022	2021
Revenue:		
Product revenue	\$ 3,163	\$ 3,162
Service and other revenue	1,868	868
Total revenue	5,031	4,030
Cost of revenue	1,785	1,416
Gross profit	3,246	2,614
Research and development costs	2,533	1,563
Sales and marketing expenses	1,845	1,575
General and administrative expenses	2,732	1,657
Operating loss	(3,864)	(2,181)
Other expense:		
Other income (expense), net	11	(25)
Interest expense, net	(106)	(332)
Net loss	\$ (3,959)	\$ (2,538)
Net loss per share attributable to common stockholders:		
Basic and diluted	\$ (0.17)	\$ (0.13)
Weighted average shares used in computing net loss per share:		
Basic and diluted	23,682,442	18,852,828

**CLEARPOINT NEURO, INC.**  
**Consolidated Balance Sheets**  
**(Dollars in thousands, except for per share data)**

March 31, 2022	December 31, 2021
-------------------	----------------------

	(Unaudited)	
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 49,658	\$ 54,109
Accounts receivable, net	2,243	2,337
Inventory, net	5,732	4,938
Prepaid expenses and other current assets	380	508
Total current assets	<u>58,013</u>	<u>61,892</u>
Property and equipment, net	709	539
Operating lease rights of use	2,116	2,241
Software license inventory	484	519
Licensing rights	352	265
Other assets	94	125
Total assets	<u>\$ 61,768</u>	<u>\$ 65,581</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 965	\$ 427
Accrued compensation	1,344	2,604
Other accrued liabilities	602	537
Operating lease liabilities, current portion	521	507
Deferred product and service revenue, current portion	541	678
Total current liabilities	<u>3,973</u>	<u>4,753</u>
Operating lease liabilities, net of current portion	1,806	1,939
Deferred product and service revenue, net of current portion	408	264
2020 senior secured convertible notes payable, net	9,851	9,838
Total liabilities	<u>16,038</u>	<u>16,794</u>
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$0.01 par value; 25,000,000 shares authorized; none issued and outstanding at March 31, 2022 and December 31, 2021	—	—
Common stock, \$0.01 par value; 200,000,000 shares authorized; 23,708,118 shares issued and outstanding at March 31, 2022; and 23,665,991 issued and outstanding at December 31, 2021	237	237
Additional paid-in capital	183,384	182,482
Accumulated deficit	(137,891)	(133,932)
Total stockholders' equity	<u>45,730</u>	<u>48,787</u>
Total liabilities and stockholders' equity	<u>\$ 61,768</u>	<u>\$ 65,581</u>

**CLEARPOINT NEURO, INC.**  
**Consolidated Statements of Cash Flows**  
(Dollars in thousands)

	For The Three Months Ended March 31,	
	2022	2021
Cash flows from operating activities:		
Net loss	\$ (3,959)	\$ (2,538)
Adjustments to reconcile net loss to net cash flows from operating activities:		
Allowance for doubtful accounts	(61)	3
Depreciation and amortization	86	15
Share-based compensation	899	320
Payment-in-kind interest	—	94
Amortization of debt issuance costs and original issue discounts	13	35
Amortization of lease rights of use, net of accretion in lease liabilities	133	133
Increase (decrease) in cash resulting from changes in:		
Accounts receivable	155	(126)
Inventory, net	(880)	47
Prepaid expenses and other current assets	128	(10)
Other assets	30	3
Accounts payable and accrued expenses	(692)	(54)
Lease liabilities	(128)	(94)
Deferred revenue	7	41
Net cash flows from operating activities	<u>(4,269)</u>	<u>(2,131)</u>
Cash flows from investing activities:		
Purchases of property and equipment	(69)	(40)
Acquisition of licensing rights	(116)	—
Net cash flows from investing activities	<u>(185)</u>	<u>(40)</u>
Cash flows from financing activities:		
Proceeds from public offering of common stock, net of offering costs	—	46,785
Proceeds from stock option and warrant exercises	3	145
Net cash flows from financing activities	<u>3</u>	<u>46,930</u>
Net change in cash and cash equivalents	<u>(4,451)</u>	<u>44,759</u>

Cash and cash equivalents, beginning of period	54,109	20,099
Cash and cash equivalents, end of period	<u>\$ 49,658</u>	<u>\$ 64,858</u>

**SUPPLEMENTAL CASH FLOW INFORMATION**

Cash paid for:

Income taxes	<u>\$ —</u>	<u>\$ —</u>
Interest	<u>\$ 100</u>	<u>\$ 214</u>




WHEN YOUR PATH IS UNCLEAR,  
WE POINT THE WAY.™

Nasdaq: CLPT

May 2022

*Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic and the measures adopted to contain its spread; future revenue from sales of the Company's ClearPoint Neuro Navigation System products; the Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation System products; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which has been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2022, which the Company intends to file with the Securities and Exchange Commission on or before May 16, 2022.*

# ClearPoint Neuro: Two Opportunities, One Platform



- A Common Installed Base Platform and Clinical Specialist Support team
- 35 Active Indications totaling more than 1 million patients diagnosed annually
- A \$12B+ Potential Total Addressable Market

## 1 A Biologics & Drug Delivery Enabling Company with;

- A unique portfolio of Navigation Tools, Infusion Cannulas, Pre-Clinical and Clinical Services
- Approximately 45 active Pharma and Academic partners

## 2 A Neuro Navigation and Device Company with;

- A growing portfolio of Navigation, Therapy and Access Devices supporting DBS, Laser Ablation, Biopsy and Brain Computer Interface implantation
- An expanding global installed base of more than 60 centers



# ClearPoint Neuro: A Proven Platform

## Key Products: FDA CE Marked Platforms

HEADQUARTERS  
Solana Beach, CA

MANUFACTURING  
Irvine, CA

EUROPEAN HEADQUARTERS  
London, UK


2022 EXPECTED REVENUE  
\$21-22m

CASH  
\$49.7m <sup>(A)</sup>

U.S. PATENTS ISSUED  
75+ <sup>(B)</sup>

GROSS MARGIN  
69% <sup>(A,C)</sup>

EMPLOYEES  
80+



[A] Unaudited as of, and for the quarter ended, March 31, 2022

[B] Including owned and licensed patents

[C] For the Trailing Twelve Months (TTM)






# Limitations of Traditional Stereotactic Neurosurgery Lack of Real-Time Image Guidance

## PRIMARY CHALLENGE

For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head

MRI is the best imaging tool for the brain

Large, metallic frames are not MRI compatible




*Big Iron companies like Siemens and Philips are innovating to make interoperative MRI scanners more accessible*



## Our Platform – Procedure Overview



# The ClearPoint® Neuro Navigation System



Leverage live MR Imaging to **Decide, Guide, Treat and Confirm** with sub-millimetric accuracy.


Our Platform

### SmartFrame® XG



SmartFrame XG Trajectory Tower with ClearPoint 2.0 Software

### SmartFrame Array™



SmartFrame Array Tower with "virtual array" Software and next generation robotic system with increased automation and enabling software\*

ClearPoint plans to translate more than 10 years of experience and over 5,000 cases performed in the complex MRI suite into unique and competitive products for the Operating Room





\*Software and Robotic System are currently under development.

Our Platform

### The ClearPoint 'Maestro' Brain Model\* Licensed and Jointly Developed with Philips

1. Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects
2. Fast and capable of peri-procedural imaging without CPU acceleration
3. This model is the basis for future navigation tools, for both the MRI suite and OR, across Biologics & Drug Delivery, DBS Navigation, Brain Computer Interface, Laser Ablation and more.



\*The ClearPoint Maestro™ Brain Model is currently under development.



Broad and Growing User Base of Leading Neurosurgery Centers

# 60+ Centers in the US, Canada and EU... and Growing Globally

UC San Francisco  
 Stanford University  
 Stanford Children's Hospital  
 UCSF Benioff Children's  
 San Francisco VA  
 USC Keck Hospital  
 UC San Diego  
 Mayo Clinic Phoenix  
 University of Colorado  
 University of Utah  
 Cook Children's Hospital  
 Texas Children's Hospital  
 MD Anderson Cancer Center  
 Houston Methodist Hospital  
 Univ. Kansas Medical Center  
 Dallas Presbyterian Hospital  
 Cincinnati Jewish  
 Children's National  
 Banner Health Tucson  
 Ohio State University  
 University of Oklahoma Medical Center  
 Methodist Hospital San Antonio  
 Barnes-Jewish Hospital  
 Cincinnati Children's Hospital

University of Wisconsin  
 University of Michigan  
 University of Minnesota  
 Cleveland Clinic  
 Northwestern Central DuPage  
 Nationwide Children's  
 Le Bonheur  
 UPMC

Charles River Labs – Laval  
 Charles River Labs – Mattawan  
 Children's Mercy Hospital  
 CHOA Scottish Rite  
 INOVA Fairfax  
 Carilion Clinic  
 Hos. Univ. of Pennsylvania  
 Children's Hospital of Alabama

Rigshospitalet (Copenhagen, Denmark)  
 Mazowiecki Szpital Bródnowski (Warsaw, Poland)  
 Hôpital Fondation Rothschild (Paris, France)  
 Skåne University Hospital (Lund, Sweden)  
 Cardiff University (United Kingdom)  
 Policlinico Umberto I (Rome, Italy)  
 Mt. Sinai West  
 Yale University  
 Weill Cornell  
 Johns Hopkins University  
 Boston Children's Hospital  
 Massachusetts General Hospital  
 Brigham & Women's  
 Duke University  
 National Institutes of Health  
 Memorial Sloan-Kettering  
 Dartmouth-Hitchcock  
 Beth Israel Deaconess  
 Children's Hospital of Philadelphia  
 Hackensack Univ. Med. Center  
 University of Virginia  
 Tampa General Hospital  
 Mayo Clinic in Florida  
 Emory University

100+  
 Centers  
 Expected  
 by 2025



Our MRI-guided therapy platform  
 is currently being used to...

CLPT PLATFORM RUNS  
 ON ALL MAJOR SCANNERS

DELIVER BIOLOGICS  
 AND DRUGS

IMPLANT NEURO  
 STIMULATION LEADS

PLACE LASER  
 ABLATION PROBES

SIEMENS



PHILIPS



LYSOGENE

uniQure



Medtronic



Medtronic  
 VISUALASE

MONTERIS  
 MEDICAL





\*In partnership with Clinical  
 Laserthermia Systems AB  
 510(k) pending



...Approximately 45 total commercial  
 and academic partners

# 2013 - 2022 Growth in Case Volume and Revenue



## ClearPoint Neuro Market Opportunity – United States

~\$12B+ Opportunity: Empowering Multiple Treatment Options for 35+ Indications\*

**Pillar 4: Global Expansion**  
~2 X U.S. Revenue

Indication	Patient Population	Annual Incidence	Pillar 1: Drug/Cell Delivery	Pillar 2: DBS & BCI	Pillar 3: Laser Ablation	Incremental Revenue from Annual Incidence
Parkinson's Disease	1,000,000 <sup>1</sup>	60,000 <sup>1</sup>	●●	●	●	\$270 M - \$1.35 B
Drug Resistant Epilepsy	1,000,000 <sup>2</sup>	11,000 <sup>3</sup>	●●	●	●	\$49.5 M - \$198 M
Refractory Essential Tremor	3,500,000 <sup>4</sup>	60,000 <sup>5</sup>		●	○	\$180 M - \$1.08 B
Brain Tumors (n=3) <sup>6</sup>	35,000 <sup>7,8</sup>	13,300 <sup>7,8</sup>	●●		●	\$33.3 M - \$300 M
Severe Obsessive-Compulsive Disorder	500,000 <sup>9,10</sup>	10,000 <sup>9,10</sup>		●		\$45 M - \$75 M
Dystonia	250,000 <sup>11</sup>	8,000 <sup>12</sup>		●		\$36 M - \$60 M
Rare Genetic/Lysosomal (n=7) <sup>13</sup>	36,500 <sup>14-18</sup>	3,000 <sup>14,19,20</sup>	●●			\$13.5 M - \$67.5 M
Paralysis / Spinal Cord (n=15) <sup>21,22</sup>	331,000 <sup>22-24</sup>	17,900 <sup>23</sup>	●●	○		\$80.6 M - \$403 M
Huntington's Disease	30,000 <sup>25</sup>	4,000 <sup>25</sup>	●●	○		\$18 M - \$90 M
Auditory Nerve Implant	1,867,000 <sup>26,27</sup>	7,000 <sup>26,27</sup>		○		\$31.5 M - \$63 M
Alzheimer's Disease	6,000,000 <sup>28</sup>	500,000 <sup>28</sup>	●●	○		\$1.5 B - \$11.3 B
Severe Major Depressive Disorder	1,000,000 <sup>10</sup>	20,000 <sup>10,29</sup>		○		\$90 M - \$150 M
Stroke Rehabilitation	2,000,000 <sup>30</sup>	610,000 <sup>30</sup>		○		\$1.83 B - \$5.49 B
Frontotemporal Dementia	60,000 <sup>31</sup>	12,000 <sup>31</sup>	○			\$54 M - \$270 M
						<b>\$4.2 B - \$20.8 B</b>

- Commercial U.S. & EU ClearPoint procedures today
- Active clinical trial
- Pre-clinical study/testing





















ClearPoint Neuro Navigation Capital, Robotics & Disposables  
Cannulas, Pumps | MER Probes | Laser Cath., Biopsy  
Access Technologies, Clinical Services, Digital Health

\*Citations & footnotes on next slide

# ClearPoint Neuro Market Opportunity – United States Citations & Footnotes

1. "Parkinson's Disease Statistics," Parkinson's News Today, <https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%208%20and%20older>
2. Neuron Therapeutics. (2021 November 4). *Neuron Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients* [Press release] [https://www.neurontherapeutics.com/wp-content/uploads/2021/11/2021\\_11\\_01\\_IND\\_Clearance\\_FINALVersion.pdf](https://www.neurontherapeutics.com/wp-content/uploads/2021/11/2021_11_01_IND_Clearance_FINALVersion.pdf)
3. Asadi-Pooya AA, Stewart GR, Abrams DJ, Sharan A. Prevalence and Incidence of Drug-Resistant Mesial Temporal Lobe Epilepsy in the United States. *World Neurosurg.* 2017;99:662-666.
4. Zesiewicz TA, Chari A, Jahan I, Miller AM, Sullivan KL. Overview of essential tremor. *Neuropsychiatr Dis Treat.* 2010;6:401-408. Published 2010 Sep 7.
5. Diaz NL, Louis ED. Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists. *Parkinsonism Relat Disord.* 2010;16(9):604-607.
6. Includes: Glioblastoma, Diffuse Intrinsic Pontine Glioma and deep small eloquent brain tumors.
7. "Glioblastoma Multiforme," American Association of Neurological Surgeons, <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme>
8. "About DIPG/DMG," DIPG/DMG Registry, <https://dipgregistry.org/patients-families/about-dipg-dmg/>
9. Medtronic Clinical Summary – Reclaim DBS for Chronic Extreme OCD M947128A001.
10. Mantovani A, Lisanby SH. Brain stimulation in the treatment of anxiety disorders. In: Simpson HB, Neria Y, Lewis-Fernández R, Schneier F, eds. *Anxiety Disorders: Theory, Research and Clinical Perspectives*. Cambridge: Cambridge University Press; 2010:323-335.
11. <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Dystonia>
12. Medtronic DBS™ Therapy for Dystonia - Clinical Summary 2015.
13. Includes: AADC deficiency, Friedreich's ataxia, Angelman syndrome, multiple system atrophy, metachromatic leukodystrophy, and spinocerebellar ataxia type 3.
14. "Multiple System Atrophy," Medscape, <https://emedicine.medscape.com/article/1154583-overview#a6>
15. PTC Therapeutics November 30, 2021 Corporate Presentation, <https://ir.ptcbio.com/static-files/0fd5d54f-55b8-416b-8006-4eb4c0d82f45>
16. "Spinocerebellar ataxia type 3," Orphanet, [https://www.orpha.net/consor/cgi-bin/OC\\_Exp.php?lng=EN&Expert=98757](https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=98757)
17. LysoGene Corporate Presentation at 38th Annual J.P. Morgan Healthcare Conference on Jan 13, 2020, [http://www.lysoGene.com/wp-content/uploads/2020/01/jpm-2020-corporate-presentation\\_final.pdf](http://www.lysoGene.com/wp-content/uploads/2020/01/jpm-2020-corporate-presentation_final.pdf)
18. "Metachromatic Leukodystrophy," National Organization of Rare Disorders, <https://rarediseases.org/rare-diseases/metachromatic-leukodystrophy/>
19. "Aromatic L-Amino Acid Decarboxylase Deficiency," National Organization of Rare Disorders, <https://rarediseases.org/rare-diseases/aromatic-l-amino-acid-decarboxylase-deficiency/>
20. Puckett Y, Mallorga-Hernández A, Montañó AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. *Orphanet J Rare Dis.* 2021;16(1):241. Published 2021 May 29.
21. Includes: stroke, spinal cord injury, multiple sclerosis, cerebral palsy, other (traumatic brain injury, complications from surgery, amyotrophic lateral sclerosis, neurofibromatosis, Chiari malformation, syringomyelia, postpolio syndrome, spinal muscular atrophy, Friedreich's ataxia, transverse myelitis, and spina bifida).
22. Armour BS, Courtney-Long EA, Fox MH, Fredine H, Cahill A. Prevalence and Causes of Paralysis-United States, 2013. *Am J Public Health.* 2016;106(10):1855-1857.
23. Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey?. *Spinal Cord.* 2006;44(9):523-529.
24. National Spinal Cord Injury Statistical Center (NSCISC). 2020 Annual Report and 2021 Facts and Figures. <https://www.nscisc.uab.edu/>
25. "Huntington's Disease," *Mov Disord.* 2019 Jun; 34(6): 858-865.
26. "Cochlear Implants," National Institute on Deafness and Other Communication Disorders, <https://www.nidcd.nih.gov/health/cochlear-implants>
27. "Cochlear Implant Surgery," Medscape, <https://emedicine.medscape.com/article/857242-overview>
28. "Alzheimer's Disease: Facts & Figures," Brightfocus Foundation, <https://www.brightfocus.org/alzheimers-disease-facts-figures>
29. Goodman WK, Alterman RL. Deep brain stimulation for intractable psychiatric disorders. *Annu Rev Med.* 2012;63:511-524.
30. "Stroke Facts," Center for Disease Control and Prevention, <https://www.cdc.gov/stroke/facts.htm>
31. Onyke CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. *Int Rev Psychiatry.* 2013;25(2):130-137.

## Innovation Pipeline ClearPoint Neuro is Dedicated to Innovation in the Neuro Space

	Expected 2022 First-Pre-Clinical/Clinical Use*	Expected First-Clinical Use by 2025*
Functional Navigation & Therapy	 <p>ClearPoint Neuro Navigation Software v. 2.1</p>  <p>ClearPoint® Array Pre-Planning Software v.1.1 &amp; SmartFrame Array™</p>  <p>Laser Ablation System</p>  <p>ClearPoint Maestro™ Brain Model</p>	 <p>Brain Computer Interface Navigation</p>  <p>Maestro Sub-Nuclei Brain Model</p>  <p>Micro-Electronic Recording System (MER)</p>  <p>CT Based Navigation w/ Maestro Brain Model</p>  <p>MR Safe and "Smart" Biopsy Needles</p>  <p>Revolution™ Robotic-Assisted Navigation Closed Loop Robotic-Assisted Navigation</p>
	 <p>Expanded Pre-Clinical Development Services for Pharma</p>  <p>Pre-Clinical Head Fixation Frame</p>  <p>ClearPoint Maestro™ Infusion Modeling App</p>  <p>Operating Room Drill</p>	 <p>Orchestra Head Fixation Frame</p>  <p>ClearPoint Maestro™ Infusion Targeting App</p>  <p>MRI Suite Safe Drill</p>  <p>Flexible, Chronic Drug Delivery Infusion Catheters</p>  <p>Spinal Infusion Catheter</p>  <p>MyClearPoint™ Patient Digital Health App</p>

New Global Showcase Site


# ClearPoint Global Training & Innovation Center – Solana Beach, CA

- Simulated training experience for surgeons and staff to perform mock procedures and provide development pipeline feedback
- Showcase new technologies to Pharmaceutical and BCI partners
- Home for Clinical Specialists to support cases remotely without travel



## 4 Pillar Growth Strategy by 2025

Target Indications of > 1,000,000 Patients Diagnosed Each Year  
Potential Total Addressable Market for CLPT of \$12B+



# CLPT Capabilities Executive Summary



**Unique platform technology**  
enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders



**Large, growing installed base**  
in 60+ of 500+ leading Neurosurgery and research centers worldwide



**Pipeline of new revenue streams**  
from product improvements, biologic and drug delivery partnerships and services, standalone therapy products, and Brain Computer Interface Navigation



**Total potential addressable market**  
> \$12B for our products, pipeline and partnerships



**Expandable Platform**  
with realizable synergies beyond the MRI and into the operating room and radiology suite



**A growing and passionate team**  
of embedded scientists and specialists





CLEARPOINT<sup>®</sup>  
NEURO

